E-polylysine hydrogel and preparation method and application thereof

Patent metadata

Field	Value
Publication number	US-9833539-B2
Application number	US-201315100222-A
Country	US
Kind code	B2
Filing date	Dec 28, 2013
Priority date	Dec 25, 2013
Publication date	Dec 5, 2017
Grant date	Dec 5, 2017

Abstract

The present invention discloses a ε-polylysine hydrogel and the preparation method and application of the as-described ε-polylysine hydrogel. The polylysine hydrogel is non-toxic to a recipient, and has biodegradability and biocompatibility. The wound tissue healing material prepared by the present invention can be used in wound tissue adhesion in an efficient, stable, safe manner.

First claim

What is claimed is:

1. A ε-polylysine hydrogel has the following constitutional unit:

wherein, n is any natural number of 20 to 30, m is any natural number of 50 to 70.

2. A process for preparing the ε-polylysine hydrogel of claim 1 , comprises the following steps:
(1) adding a polyethylene glycol into dichlormethane, adding 4-dimethylaminopyridine and triethylamine reacting for 20˜150 min at room temperature; then adding dropwisely the reaction mixture into a solution of p-nitrophenylchloroformate in dichlormethane under inert gas shielding condition at room temperature, reacting for 12 to 72 hours; evaporating and then adding dropwisely into a cold diethyl ether solution; removing precipitates from mixed solution by filtration and vacuum freeze-drying to obtain a p-nitrophenylchloroformate-polyethylene glycol-p-nitrophenylchloroformate copolymer;
(2) dissolving the p-nitrophenylchloroformate-polyethylene glycol-p-nitrophenylchloroformate copolymer into a phosphate buffer; then adding a tyramine dissolved in the phosphate buffer, reacting for 5 to 72 hours at room temperature to obtain a solution of p-nitrophenylchloroformate-polyethylene glycol-tyramine copolymer;
(3) dissolving a ε-polylysine into the phosphate buffer, then adding the p-nitrophenylchloroformate-polyethylene glycol-tyramine copolymer solution from step (2), and reacting at room temperature for 12 to 72 hours; removing the p-nitrophenylchloroformate precipitate by filtration, following by dialyzing the filtrate in purified water for 4 to 8 days; freeze-drying the filtrate to obtain a ε-polylysine grafted with polyethylene glycol and tyramine;
(4) dissolving the ε-polylysine-polyethylene glycol-tyramine from step (3) into the water or phosphate buffer; adding a mixed aqueous solution of horseradish peroxidase and hydrogen peroxide; and stirring for 5 to 60 seconds at room temperature to form the ε-polylysine hydrogel.

3. The process according to claim 2 , characterized in that, in step (1), dissolving polyethylene glycol in dichlormethane, such that the concentration of the solute polyethylene glycol is 50 to 200 g/L; in the solution of p-nitrophenylchloroformate in dichlormethane, the concentration of the solute p-nitrophenylchloroformate is 20 to 40 g/L.

4. The process according to claim 2 , characterized in that, in step (1), the reaction mole ratio of polyethylene glycol, 4-dimethylaminopyridine, triethylamine, p-nitrophenylchloroformate is 1:2 to 5:2 to 5:2 to 5.

5. The process according to claim 2 , characterized in that, in step (1), the temperature of the cold diethyl ether is −4° C. to −20° C., the amount of the cold diethyl ether is 20 to 40 fold of volume of the reaction solution after the evaporation.

6. The process according to claim 2 , characterized in that, in step (1), the temperature of the vacuum freeze-drying is −40° C. to −80° C., and the pressure is 10 to 30 Pa.

7. The process according to claim 2 , characterized in that, in step (1), all reactions are conducted under the room temperature and anhydrous and oxygen-free condition.

8. The process according to claim 2 , characterized in that, in step (2), (3) and (4), the phosphate buffer being a phosphate buffer of pH 7.4 and 0.01 to 0.2 mol/L.

9. The process according to claim 2 , characterized in that, in step (2), dissolving p-nitrophenylchloroformate-polyethylene glycol-p-nitrophenylchloroformate copolymer in the phosphate buffer, the concentration of the solute nitrophenyl chloroformate-polyethylene glycol-p-nitrophenylchloroformate copolymer is 50 to 100 g/L; in the tyramine phosphate buffer, the concentration of the tyramine is 3 to 10 g/L.

10. The process according to claim 2 , characterized in that, in step (2), the mole ratio of p-nitrophenylchloroformate-polyethylene glycol-p-nitrophenylchloroformate copolymer to tyramine is 2:0.5 to 1.5.

11. The process according to claim 2 , characterized in that, in step (2), all reactions are conducted under the room temperature and oxygen-free condition.

12. The process according to claim 2 , characterized in that, in step (3), dissolving polylysine in the phosphate buffer, and the concentration of the polylysine is 0.43 to 1.09 g/L.

13. The process according to claim 2 , characterized in that, in step (3), the mole ratio of ε-polylysine to p-nitrophenylchloroformate-polyethylene glycol-p-nitrophenylchloroformate copolymer is 0.04 to 0.07:2.

14. The process according to claim 2 , characterized in that, in step (3), all reactions are conducted under the room temperature and oxygen-free condition.

15. The process according to claim 2 , characterized in that, in step (4), dissolving the ε-polylysine grafted with PEG (polyethylene glycol) and tyramine obtained in step (3) in water or phosphate buffer, the concentration of the ε-polylysine grafted with PEG (polyethylene glycol) and tyramine is 10 to 15% of weight.

16. The process according to claim 2 , characterized in that, in step (4), in the mixed aqueous solution of horseradish peroxidase and hydrogen peroxide, the concentration of the solute horseradish peroxidase and hydrogen peroxide in aqueous solution is 0.003 to 0.12 mg/mL and 0.02 to 0.07% of weight, respectively.

17. The process according to claim 2 , characterized in that, in step (4), all reactions are conducted under the room temperature and oxygen-free condition.

18. A process for treating a wound comprising a step of administering the ε-polylysine hydrogel of claim 1 to a patient in need of would treatment.

Assignees

• Nanjing Tech Univ (Cn)
• Nanjing University Of Technology

Inventors

• Xu Hong
• Chi Bo
• Wang Rui
• Feng Xiaohai
• Li Sha
• Liang Jinfeng
• Ouyang Pingkai

Classifications

• A61L26/0047

  Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042 · CPC title

• A61L15/32

  Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)} · CPC title

• A61L15/60

  Liquid-swellable gel-forming materials, e.g. super-absorbents · CPC title

• C08G69/10

  Alpha-amino-carboxylic acids {(polysuccinimides C08G73/1092)} · CPC title

• A61L26/008

  Hydrogels or hydrocolloids · CPC title